Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Enlyton publishes cancer imaging study results of colorectal cancer

Enlyton, Ltd., announced the publication of a cancer imaging study in which Enlyton's antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, 18F-FDG, in Positron Emission Tomography (PET) imaging of colorectal cancer.

13 Sep 2010

Children with severe, therapy-resistant asthma more likely to have poorer lung function: SARP

A subset of children with asthma suffers from severe, treatment-resistant disease associated with more illness and greater allergic hypersensitivity, according to the results of the National Heart, Blood, and Lung Institute's Severe Asthma Research Program, presented in a recently published article in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc..

10 Sep 2010

Halozyme Therapeutics announces public offering of 8.3 million shares of common stock

Halozyme Therapeutics, Inc. today announced the pricing of its previously announced public offering of 8.3 million shares of its common stock at a price to the public of $7.50 per share.

10 Sep 2010

ESC recommends InspireMD MGuard mesh technology for thrombotic lesions

InspireMD Ltd., a medical device company engaged in the development and commercialization of the mesh based MGuard(TM) stent systems, is proud to report that mesh-based protection, is now recommended for use in the new Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC). According to the latest European Society of Cardiology Guidelines, published at the ESC Congress last week, "Mesh-based protection may be considered for PCI of highly thrombotic or SVG lesions" - it has received a class IIb recommendation.

9 Sep 2010

Halozyme Therapeutics offers to sell 8.3 million shares of common stock

Halozyme Therapeutics, Inc. today announced that it is offering to sell 8.3 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering

9 Sep 2010

Children's Hospital Boston engages Particle Sciences for drug product development services

Particle Sciences Inc. (PSI), a leading pharmaceutical Contract Research Organization (CRO), has been engaged by Children's Hospital Boston to help advance early stage molecules and drug innovations into new therapeutic products for patient care. Under the established framework between Children's and PSI, Particle Sciences provides drug product development services aimed at progressing the specific drug or drug product candidate to the point where it becomes attractive to potential licensees.

8 Sep 2010

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

Celsion Corporation, a biotechnology drug development company, announced today that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, "New Thermal Sensitive Carboplatin Liposomes for Cancer".

3 Sep 2010

Purdue University researchers develop new type of pump for drug-delivery patches

Purdue University researchers have developed a new type of pump for drug-delivery patches that might use arrays of "microneedles" to deliver a wider range of medications than now possible with conventional patches.

2 Sep 2010

Halozyme initiates Ultrafast Insulin combination Phase 2 studies with rHuPH20

Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.

2 Sep 2010

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.

2 Sep 2010

pSivida announces FDA Priority Review status for Iluvien NDA

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME).

31 Aug 2010

Halozyme identifies strategy to reintroduce HYLENEX

Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.

31 Aug 2010

SCOLR Pharma signs sales support agreement with Emerson Group

SCOLR Pharma, Inc. today announced that it has signed an agreement with The Emerson Group to provide sales support for the Company's new line of extended-release nutritional and over-the-counter drug products.

31 Aug 2010

Biotage launches new Resolux line of HPLC columns optimized for peptide purification

Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, has launched a new range of HPLC columns optimized for peptide purification. The Resolux™ line was introduced during the ACS Fall 2010 National Meeting & Exposition in Boston, Massachusetts USA and will be premiered at the 31st European Peptide Symposium on September 5th in Copenhagen, Denmark.

31 Aug 2010

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).

31 Aug 2010

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

Elan Corporation, plc announced today that Elan's wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., commenced an offer to purchase of up to $186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" together with the 2013 Fixed Rate Notes, the "2013 Notes"),

31 Aug 2010

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

BioDelivery Sciences International, Inc. announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.

30 Aug 2010

Otonomy announces closing of $38.5 million Series B financing

Otonomy, Inc. announced today that it has closed a $38.5 million Series B financing co-led by Novo Ventures and RiverVest Venture Partners, and joined by Domain Associates and TPG Biotech. This financing is incremental to the $10 million Series A closed with Avalon Ventures in June 2010. Avalon also participated in the Series B round.

30 Aug 2010

Xcellerex, SK Chemicals sign memorandum of understanding to expand vaccine business in Korea

Xcellerex, Inc. announced today that it has signed a memorandum of understanding with SK Chemicals, Co., Ltd., one of South Korea's largest industrial groups, for an alliance to develop and commercialize SK-developed vaccines with Xcellerex's FlexFactory biomanufacturing platform. The companies expect to define specific terms of the alliance in the coming months.

26 Aug 2010

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

Alexza Pharmaceuticals, Inc. announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking. The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by delivering nicotine via inhalation, mimicking the nicotine effects of smoking without the harmful side effects associated with cigarettes.

26 Aug 2010

Drug Delivery News and Research

Further Reading

Enlyton publishes cancer imaging study results of colorectal cancer

Children with severe, therapy-resistant asthma more likely to have poorer lung function: SARP

Halozyme Therapeutics announces public offering of 8.3 million shares of common stock

ESC recommends InspireMD MGuard mesh technology for thrombotic lesions

Halozyme Therapeutics offers to sell 8.3 million shares of common stock

Children's Hospital Boston engages Particle Sciences for drug product development services

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

Purdue University researchers develop new type of pump for drug-delivery patches

Halozyme initiates Ultrafast Insulin combination Phase 2 studies with rHuPH20

Celator Pharmaceuticals raises $20 million in Series D private equity financing

pSivida announces FDA Priority Review status for Iluvien NDA

Halozyme identifies strategy to reintroduce HYLENEX

SCOLR Pharma signs sales support agreement with Emerson Group

Biotage launches new Resolux line of HPLC columns optimized for peptide purification

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

Otonomy announces closing of $38.5 million Series B financing

Xcellerex, SK Chemicals sign memorandum of understanding to expand vaccine business in Korea

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

Event guide: World ADC San Diego eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo